Guanfacine Dosing for 100-lb Patient with ADHD
For a 100-lb (approximately 45 kg) patient with ADHD, the appropriate guanfacine extended-release dose is approximately 4-5 mg once daily, based on the weight-adjusted dosing recommendation of 0.1 mg/kg/day. 1
Weight-Based Dosing Algorithm
The most recent guidelines establish clear weight-based dosing for guanfacine extended-release in ADHD:
- Starting dose: 0.05-0.08 mg/kg/day 2
- Target maintenance dose: 0.1 mg/kg/day (rule of thumb) 1
- Maximum dose: Up to 0.12 mg/kg/day if tolerated and additional benefit is needed 2, 3
Calculation for 100-lb (45 kg) Patient:
- Initial target: 45 kg × 0.1 mg/kg = 4.5 mg/day (round to 4 mg)
- Potential maximum: 45 kg × 0.12 mg/kg = 5.4 mg/day (round to 5 mg if needed)
Titration Schedule
Start conservatively and titrate up:
- Begin at 1 mg once daily (typically at bedtime to minimize somnolence) 1
- Increase by 1 mg weekly based on tolerability
- Target dose of 4 mg once daily for this weight
- May increase to 5 mg daily if response is suboptimal and medication is well-tolerated 3
Important Clinical Considerations
Timing of administration: Evening dosing is generally preferable due to frequent somnolence and fatigue, which typically emerge within the first 2 weeks and often resolve over time 1, 4. However, once-daily dosing can be given at any consistent time.
Common adverse effects to monitor (occur in >10% of patients) 1, 4:
- Somnolence (most common at 38.6%)
- Headache (20.5%)
- Fatigue (15.2%)
- Bradycardia and hypotension (dose-dependent)
- Dizziness and postural dizziness
Critical safety monitoring 5:
- Obtain personal and family cardiac history before initiation
- Monitor blood pressure and heart rate at baseline and during treatment
- Expect mild decreases in BP (average 1-4 mm Hg) and HR (1-2 beats per minute)
- Perform ECG if cardiac risk factors are present
Key Pitfall: Abrupt Discontinuation
Never stop guanfacine abruptly. Rebound hypertension can occur 2-4 days after sudden discontinuation 5, 1. Always taper the medication gradually when discontinuing.
Drug Interactions
If the patient is taking moderate CYP3A4 inhibitors (erythromycin, fluconazole), decrease the guanfacine dose to 50% of the target dose 6. If taking moderate CYP3A4 inducers (efavirenz), consider titrating up to double the usual dose over 1-2 weeks 6.
Efficacy Timeline
Set appropriate expectations: Unlike stimulants which work immediately, guanfacine requires 2-4 weeks to observe treatment effects 1. This is a critical counseling point to prevent premature discontinuation.
Role in Treatment Algorithm
Guanfacine is FDA-approved as monotherapy or adjunctive therapy to stimulants 5, 1. Current guidelines position it as second-line treatment when stimulants are not suitable, not tolerated, or ineffective, though it has smaller effect sizes than stimulants 1. It may be considered first-line in patients with comorbid tic disorders, substance use concerns, or when stimulant side effects are prohibitive 1.